Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 8
1990 8
1991 7
1992 12
1993 7
1994 7
1995 6
1996 3
1997 13
1998 8
1999 12
2000 6
2001 8
2002 11
2003 11
2004 12
2005 11
2006 14
2007 13
2008 17
2009 19
2010 24
2011 17
2012 25
2013 22
2014 36
2015 20
2016 21
2017 31
2018 25
2019 37
2020 42
2021 44
2022 35
2023 43
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

587 results

Results by year

Filters applied: . Clear all
Page 1
Evolving classification of rhabdomyosarcoma.
Agaram NP. Agaram NP. Histopathology. 2022 Jan;80(1):98-108. doi: 10.1111/his.14449. Histopathology. 2022. PMID: 34958505 Free PMC article. Review.
MYOD1 as a prognostic indicator in rhabdomyosarcoma.
Ahmed AA, Habeebu S, Farooqi MS, Gamis AS, Gonzalez E, Flatt T, Sherman A, Surrey L, Arnold MA, Conces M, Koo S, Dioufa N, Barr FG, Tsokos MG. Ahmed AA, et al. Pediatr Blood Cancer. 2021 Sep;68(9):e29085. doi: 10.1002/pbc.29085. Epub 2021 Apr 29. Pediatr Blood Cancer. 2021. PMID: 33913590 Free PMC article.
SRMS harbors MYOD1 mutations in a subset of adult cases in association with poor prognosis. ...CONCLUSION: These studies highlight the prognostic role of MYOD1 in non-ARMS. Lack of MYOD1 immunoreactivity is associated with poor prognosis in ERMS and SRMS. ...
SRMS harbors MYOD1 mutations in a subset of adult cases in association with poor prognosis. ...CONCLUSION: These studies highlight th …
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, Yohe ME, Sindiri S, Wei J, Wen X, Rudzinski ER, Barkauskas DA, Lo T, Hall D, Linardic CM, Hughes D, Jamal S, Jenney M, Chisholm J, Brown R, Jones K, Hicks B, Angelini P, George S, Chesler L, Hubank M, Kelsey A, Gatz SA, Skapek SX, Hawkins DS, Shipley JM, Khan J. Shern JF, et al. J Clin Oncol. 2021 Sep 10;39(26):2859-2871. doi: 10.1200/JCO.20.03060. Epub 2021 Jun 24. J Clin Oncol. 2021. PMID: 34166060 Free PMC article.
Interestingly, mutations in RAS isoforms predominated in infants < 1 year (64% of cases). Mutation of MYOD1 was associated with histologic patterns beyond those previously described, older age, head and neck primary site, and a dismal survival. ...

Interestingly, mutations in RAS isoforms predominated in infants < 1 year (64% of cases). Mutation of MYOD1 was associated with hi

…
MyoD1 suppresses cell migration and invasion by inhibiting FUT4 transcription in human gastric cancer cells.
Wu F, Qin Y, Jiang Q, Zhang J, Li F, Li Q, Wang X, Gao Y, Miao J, Guo C, Yang Y, Ni L, Liu L, Zhang S, Huang C. Wu F, et al. Cancer Gene Ther. 2020 Nov;27(10-11):773-784. doi: 10.1038/s41417-019-0153-3. Epub 2019 Dec 12. Cancer Gene Ther. 2020. PMID: 31831855 Free PMC article.
MyoD1 is expressed at significantly lower levels in gastric cancer (GC) tissues and cells, and it induces apoptosis in GC cells. ...We show that knockdown of MyoD1 promoted migration and invasion of GC cells, whereas MyoD1 overexpression suppressed mig …
MyoD1 is expressed at significantly lower levels in gastric cancer (GC) tissues and cells, and it induces apoptosis in GC cell …
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S, Linardic CM, Kelsey A, Rudzinski ER, Vokuhl C, Selfe J, Ruhen O, Shern JF, Khan J, Kovach AR, Lupo PJ, Gatz SA, Schäfer BW, Volchenboum S, Minard-Colin V, Koscielniak E, Hawkins DS, Bisogno G, Sparber-Sauer M, Venkatramani R, Merks JHM, Shipley J. Hettmer S, et al. Eur J Cancer. 2022 Sep;172:367-386. doi: 10.1016/j.ejca.2022.05.036. Epub 2022 Jul 12. Eur J Cancer. 2022. PMID: 35839732 Free article. Review.
We review relevant data and present a consensus view on what molecular features should be assessed. In particular, we recommend the assessment of the MYOD1-LR122R mutation for risk escalation, as it has been associated with poor outcomes in spindle/sclerosing RMS and rare …
We review relevant data and present a consensus view on what molecular features should be assessed. In particular, we recommend the assessme …
Biological Role and Clinical Implications of MYOD1(L122R) Mutation in Rhabdomyosarcoma.
Di Carlo D, Chisholm J, Kelsey A, Alaggio R, Bisogno G, Minard-Colin V, Jenney M, Dávila Fajardo R, Merks JHM, Shipley JM, Selfe JL. Di Carlo D, et al. Cancers (Basel). 2023 Mar 7;15(6):1644. doi: 10.3390/cancers15061644. Cancers (Basel). 2023. PMID: 36980529 Free PMC article. Review.
MYOD1(L122R) mutations can be found together with mutations in other genes, such as PIK3CA, as potentially cooperating events. ...MYOD1(L122R) mutated tumors most frequently arise in the head and neck and extremities and are associated with poor outcome, raising the …
MYOD1(L122R) mutations can be found together with mutations in other genes, such as PIK3CA, as potentially cooperating events. ... …
The Association of Methylation Status and Expression Level of MyoD1 with DNMT1 Expression Level in Breast Cancer Patients.
Khojastehpour S, Foroughi F, Gheibi N, Mohammadi Z, Ahmadi MH, Nasirian N, Maali A, Azad M. Khojastehpour S, et al. Int J Hematol Oncol Stem Cell Res. 2023 Jul 1;17(3):133-144. doi: 10.18502/ijhoscr.v17i3.13303. Int J Hematol Oncol Stem Cell Res. 2023. PMID: 37817971 Free PMC article.
Background: Breast cancer (BC) is the most common malignancy in women worldwide. The methylation status of MyoD1, a tumor suppressor gene, is enrolled in various cancers, i.e., BC. ...In addition, in BC patients, the reduced expression level of MyoD1 w …
Background: Breast cancer (BC) is the most common malignancy in women worldwide. The methylation status of MyoD1, a tumor supp …
MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/beta-Catenin and MYOD1/Caspase-3 Signaling Pathways.
Zhao L, Liu Y, Tong D, Qin Y, Yang J, Xue M, Du N, Liu L, Guo B, Hou N, Han J, Liu S, Liu N, Zhao X, Wang L, Chen Y, Huang C. Zhao L, et al. EBioMedicine. 2017 Feb;16:87-100. doi: 10.1016/j.ebiom.2017.01.021. Epub 2017 Jan 17. EBioMedicine. 2017. PMID: 28131747 Free PMC article.
Methyl-CpG binding protein 2 (MeCP2) has recently been characterized as an oncogene frequently amplified in several types of cancer. However, its precise role in gastric cancer (GC) and the molecular mechanism of MeCP2 regulation are still largely unknown. ...The re …
Methyl-CpG binding protein 2 (MeCP2) has recently been characterized as an oncogene frequently amplified in several types of cancer. …
MyoD1 expression in fibroepithelial stromal polyps.
Olson NJ, Fritchie KJ, Torres-Mora J, Folpe AL. Olson NJ, et al. Hum Pathol. 2020 May;99:75-79. doi: 10.1016/j.humpath.2020.03.006. Epub 2020 Mar 23. Hum Pathol. 2020. PMID: 32217091
Recently, we encountered a cellular FESP showing desmin expression as well as nuclear immunoreactivity for the skeletal muscle-associated transcription factor MyoD1. Although these lesions are widely known to express desmin, there are very few studies examining expression …
Recently, we encountered a cellular FESP showing desmin expression as well as nuclear immunoreactivity for the skeletal muscle-associated tr …
587 results